Sage Therapeutics depression drug disappoints

New data from trial involving a drug treating severe depression disappoints the stock market, and biotech company Sage Therapeutics faces share price decline.
Photo: CARLO ALLEGRI/REUTERS / X90181
Photo: CARLO ALLEGRI/REUTERS / X90181
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading